

January 2017 APC Decisions

Medicine	Classification	Indication	Other Information
Degarelix (Firmagon®) NICE TA 404	AMBER 2	Advanced hormone-dependent prostate cancer	An option for treating advanced hormone-dependent prostate cancer in people with spinal metastases. To be initiated in secondary care
Methenamine	AMBER 2	Recurrent urinary tract infections	Treatment of recurrent urinary tract infections in adults with symptomatic episodes requiring antibiotic treatment more than 8 times per year.

For a full explanation of the Traffic Light definitions, please refer to the [Joint Formulary website](#)

News from the APC

New to the APC website

- [Antibiotic prophylaxis for recurrent UTI \(New\)](#)
- [Methotrexate shared care for gastroenterology and associated information sheet \(New\)](#)
- [Phosphate binders for the treatment of Hyperphosphataemia Shared Care Protocol \(Update\)](#)
- [Anticoagulants in AF guideline \(Update\)](#)

Coming soon to the APC website

- *Heart Failure Traffic Light Treatment Guideline (Update)*
- *Management of hyperlipidaemia in primary care guideline (New)*
- *Ocular lubricants formulary*

Midodrine monitoring...

Please remember the on-going monitoring which is required in primary care:

Frequency of monitoring	Test to be done		
	Lying and standing blood pressure	Renal function	LFTs
Minimum 6 monthly or if symptoms recur	✓	✓	✓

Can you help?

We are currently looking for additional **GP members** to represent the County CCGs. Are you someone with an interest in all things prescribing who is able to commit to attend and contribute at the APC meetings? We meet every 2 months on a Thursday afternoon (2-5pm) at Duncan Macmillan House. Please contact us if you would like to get involved.

Horizon Scanning, Formulary amendments and traffic light changes

Formulary amendments

- Sevelamer—Formulary classification for sevelamer carbonate changed to **AMBER 1**. Renagel® changed to **GREY** (non-formulary).
- Doxepin—Formulary amendment added stating doxepin is second line to amitriptyline for itching. Amendment added to amitriptyline stating first line in itching.
- Tiotropium—Braltus® brand added to tiotropium entry.
 - Despite being different doses: Spiriva Handihaler and Braltus are bioequivalent and deliver the same amount of active ingredient to the patient
 - Capsules for Spiriva Handihaler and Braltus should be used in their intended device only
- Fluoride—**AMBER 2** classification agreed. For radiotherapy patients only; it will be appropriate for the GP to prescribe until the patients register with a dentist. All patients should be encouraged to register with a dentist.

Current work in development

- Pilocarpine tablets formulary submission
- Review of Nottinghamshire formulary GREY classification
- Type 2 Diabetes guidelines (Update)
- Emollient Formulary (Review)
- Smoking cessation guideline (Update)
- Sip feeds guideline (Update)
- Prescribing of nebulised colistimethate—Colymycin® (Update)

Upcoming NICE guidance

Spondyloarthritis	Guideline	February 2017
Parkinsons' Disease	Guideline	April 2017

The work of the NAPC is supported and managed by the interface team below. They can be contacted via nottsapc@nottspct.nhs.uk if you would like to make a submission or have any queries.

Laura Catt, Prescribing Interface Advisor, NHS Mansfield and Ashfield CCG

Nick Sherwood, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Daniel Shipley, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Irina Varlan, Specialist Interface and Formulary Pharmacist, Nottingham University Hospitals NHS Trust